Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company | Contract Pharma

What are you searching for?

Sign in
Breaking News

Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or best-in-class potential.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Verdiva Bio Ltd. has launched as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. The company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Verdiva launches with an Series A financing of $411million, co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.

Khurem Farooq, formerly the CEO of Aiolos Bio and Gyroscope Therapeutics, will serve as Chief Executive Officer leading an experienced team of drug developers and biotech company builders.

Verdiva acquired global development and commercialization rights outside of greater China and South Korea to their portfolio from Sciwind Biosciences in 2024. Verdiva plans to advance the development of these therapies via a mix of monotherapy and combination programs, including: a phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist; a potential first-in-class, once-weekly oral amylin agonist for use as monotherapy or in combination with an oral GLP-1 agonist; and a long-acting, subcutaneous amylin agonist for use as monotherapy or in combination with a proprietary GLP-1 peptide.

“People living with obesity and its complications deserve better options at each stage of their treatment journey, including oral therapies with less frequent dosing regimens, the potential for improved efficacy and tolerability, and innovative combination therapies in pursuit of healthier weight loss and, equally importantly, maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs,” said Farooq.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics